Published in

Springer Nature [academic journals on nature.com], Signal Transduction and Targeted Therapy, 1(6), 2021

DOI: 10.1038/s41392-021-00670-9

Links

Tools

Export citation

Search in Google Scholar

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Journal article published in 2021 by Kai Li, Houhui Shi, Benxia Zhang, Xuejin Ou, Qizhi Ma, Yue Chen, Pei Shu, Dan Li, Yongsheng Wang
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

AbstractMyeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly but also promote tumor invasion via various non-immunological activities. Besides, this group of cells are proved to impair the efficiency of current antitumor strategies such as chemotherapy, radiotherapy, and immunotherapy. Therefore, MDSCs are considered as potential therapeutic targets for cancer therapy. Treatment strategies targeting MDSCs have shown promising outcomes in both preclinical studies and clinical trials when administrated alone, or in combination with other anticancer therapies. In this review, we shed new light on recent advances in the biological characteristics and immunosuppressive functions of MDSCs. We also hope to propose an overview of current MDSCs-targeting therapies so as to provide new ideas for cancer treatment.